Supportive Care in Cancer

, Volume 27, Issue 5, pp 1679–1686 | Cite as

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit

  • Florent PuissetEmail author
  • Laurence Bigay-Game
  • Marie Noëlle Paludetto
  • Audrey Martel
  • Sophie Perriat
  • Audrey Rabeau
  • Jean Marie Canonge
  • Julien Mazieres
Original Article



Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice.


We collected medical records from patients treated by cisplatin for lung cancer in our unit between 2010 and 2016. We retrospectively analyzed the incidence of cisplatin induced nephrotoxicity between after and before the change of hydration regimen.


Our patient cohort included 241 patients hydrated by intravenous regimen (IV/IV group) and 276 patient hydrated by intravenous and oral regimen (IV/PO group). Grade ≥ 1 nephrotoxicity occurred in 39.4 and 25.7% in the IV/IV and IV/PO groups respectively (p = 0.001). Age over 70 at baseline was a predictive factor for nephrotoxicity, but not estimated glomerular filtration rate nor cisplatin-associated drugs. After a multivariate analysis, age remained a predictive factor for nephrotoxicity and IV/PO hydration associated with a decrease in nephrotoxic risk.


The implementation of oral hydration in our practice was not associated with an increase in nephrotoxicity. Our observation based on large data from clinical practice shows that oral hydration after cisplatin is safe.


Lung cancer Cisplatin Nephrotoxicity Oral hydration Outpatient 


Compliance with ethical standards

This study was performed in the respect for ethical consideration of research involving human participant. Since it was a retrospective study based on existing data, formal consent is not required.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH, American Society of Clinical Oncology Clinical Practice (2015) Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(30):3488–3515. CrossRefGoogle Scholar
  2. 2.
    Facchetti G, Petrella F, Spaggiari L, Rimoldi I (2017) Malignant pleural mesothelioma: state of the art and advanced cell therapy. Eur J Med Chem 142:266–270. CrossRefGoogle Scholar
  3. 3.
    Kalemkerian GP (2014) Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 15(16):2385–2396. CrossRefGoogle Scholar
  4. 4.
    Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2(11):2490–2518. CrossRefGoogle Scholar
  5. 5.
    Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007. CrossRefGoogle Scholar
  6. 6.
    Oh G-S, Kim H-J, Shen A, Lee SB, Khadka D, Pandit A, So HS (2014) Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press E BP 12(2):55–65. CrossRefGoogle Scholar
  7. 7.
    Launay-Vacher V, Rey J-B, Isnard-Bagnis C, Deray G, Daouphars M (2008) European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61(6):903–909. CrossRefGoogle Scholar
  8. 8.
    Fukushima K, Okada A, Oe H, Hirasaki M, Hamori M, Nishimura A, Shibata N, Sugioka N (2018 Apr) Pharmacokinetic-pharmacodynamic analysis of cisplatin with hydration and mannitol diuresis: the contribution of urine cisplatin concentration to nephrotoxicity. Eur J Drug Metab Pharmacokinet 43(2):193–203. CrossRefGoogle Scholar
  9. 9.
    Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40(4):293–308. CrossRefGoogle Scholar
  10. 10.
    Lavolé A, Danel S, Baudrin L et al (2012) Routine administration of a single dose of cisplatin ≥75mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer (Paris) (4):43–48.
  11. 11.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130(6):461–470CrossRefGoogle Scholar
  12. 12.
    Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute dialysis quality initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care Lond Engl 8(4):R204–R212. CrossRefGoogle Scholar
  13. 13.
    Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54(1):19–23CrossRefGoogle Scholar
  14. 14.
    Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer Oxf Engl 1990 44(17):2608–2614. Google Scholar
  15. 15.
    Furukawa N, Kawaguchi R, Kobayashi H (2012) Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care (Engl) 21(4):436–441. CrossRefGoogle Scholar
  16. 16.
    Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5(2):304–309. CrossRefGoogle Scholar
  17. 17.
    Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R (2015) Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer 89(2):161–166. CrossRefGoogle Scholar
  18. 18.
    Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65(2):307–314CrossRefGoogle Scholar
  19. 19.
    Sato K, Watanabe S, Ohtsubo A et al (2016) Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16(1).
  20. 20.
    Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, di Salvia R, de Marinis F, Ardizzoni A (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93(2):138–144CrossRefGoogle Scholar
  21. 21.
    Ouchi A, Asano M, Aono K, Watanabe T, Kato T (2014) Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose cisplatin. J Oncol 2014:1–4. CrossRefGoogle Scholar
  22. 22.
    Yamaguchi T, Uozu S, Isogai S, Hayashi M, Goto Y, Nakanishi T, Imaizumi K (2017) Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis. Support Care Cancer 25(4):1215–1220. CrossRefGoogle Scholar
  23. 23.
    Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43(11):1115–1123. CrossRefGoogle Scholar
  24. 24.
    Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21(1):81–87. CrossRefGoogle Scholar
  25. 25.
    Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T (2013) Short hydration in chemotherapy containing cisplatin (>=75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43(11):1105–1109. CrossRefGoogle Scholar
  26. 26.
    Sato J, Morikawa N, Nitanai H et al (2016) Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer. J Pharm Health Care Sci 2(1).
  27. 27.
    Mor V, Stalker MZ, Gralla R, Scher HI, Cimma C, Park D, Flaherty AM, Kiss M, Nelson P, Laliberte L, Schwartz R, Marks PA, Oettgen HF (1988) Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. J Clin Epidemiol 41(8):771–785CrossRefGoogle Scholar
  28. 28.
    Azzoli CG, Baker S, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(36):6251–6266. CrossRefGoogle Scholar
  29. 29.
    Azuma T, Matayoshi Y, Sato Y, Sato Y, Nagase Y, Oshi M (2016) The safety and effect of chemotherapy with short hydration for urothelial cancer on patients’ quality of life. Jpn J Clin Oncol 46(10):958–963. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmacy department IUCT (Institut Universitaire du Cancer) OncopoleInstitut Claudius RegaudToulouseFrance
  2. 2.CRCT (Cancer Research Centre of Toulouse)Université de Toulouse, Inserm UMR 1037, Université Paul SabatierToulouse Cedex 9France
  3. 3.PharmacieInstitut Universitaire du Cancer Toulousain-OncopoleToulouse Cedex 9France
  4. 4.Thoracic Oncology Department, Larrey HospitalUniversity Hospital ToulouseToulouseFrance
  5. 5.Pharmacy department IUCT (Institut Universitaire du Cancer) OncopoleUniversity Hospital ToulouseToulouseFrance
  6. 6.Université Paul SabatierToulouseFrance

Personalised recommendations